Abstract
Background: Chronic kidney disease is a heterogeneous group of disorders involving changes in kidney structure and function. For many decades they thought that hyperuricemia causes impairment to renal function through retention of uric acid caused by impaired renal excretion. Allopurinol has been the mainstay therapy for gout and hyperuricemia associated conditions for a long time. Allopurinol has a rare but serious hypersensitivity reaction CKD patients are at higher risk of this complication. Febuxostat drug is a new potent agent which seems to be tolerable in patients involving those who develop Allopurinol sensitivity. It is a non- purine compound; It selectively inhibit xanthine oxidoreductase enzyme
Aim: To assess the renoprotective effect of Febuxostat in comparison with Allopurinol in hyperuricemic CKD patients stage 3 and 4.
Material and methods: This retrospective study included 300 patients selected from Renal outpatient clinic at Alexandria Main University Hospital and private clinics.
• 150 patients CKD stage (3,4) with hyperuricemia treated with Febuxostat renal modified dose.
• 150 patients CKD stage (3,4) with hyperuricemia treated with Allopurinol renal modified dose.
Results: In Febuxostat group than Allopurinol group at 6 months (u=8644.5, p=0.001) and 12 months (u=6316.0, p <0.001). At 6 months and 12 months data revealed no significant difference in eGFR slopes between the Febuxostat and Allopurinol groups
Keywords: Chronic Kidney Disease, Hyperuricemia, Allopurinol, Febuxostat.